Ju-Young Shin1,2, Maria Eberg1, Pierre Ernst1,3, Kristian B Filion1,2,3. 1. Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada. 2. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada. 3. Department of Medicine, McGill University, Montreal, Quebec, Canada.
Abstract
AIM: Previous studies suggest that statins may have beneficial respiratory effects. However, it is unclear if these purported benefits vary with statin potency. Our objective was to determine if higher potency statins, compared with lower potency statins, were associated with a reduced risk of hospitalization for community-acquired pneumonia (HCAP). METHODS: We conducted a nested case-control analysis of a retrospective, population-based cohort of new users of statins using data extracted from the UK's Clinical Practice Research Datalink and Hospital Episode Statistics. For each HCAP case, we used risk set sampling to randomly select up to 10 controls, matched on sex, age, cohort entry date and follow-up duration. We used conditional logistic regression with high-dimensional propensity scores to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for HCAP with current use of higher potency statin vs. lower potency statins. RESULTS: A total of 217 721 patients entered the cohort on a lower potency statin and 130 707 entered on a higher potency statin; these patients resulted in 2251 cases of HCAP during 561 886 person-years of observation (rate: 4.0 HCAP per 1000 persons per year, 95% CI: 3.8-4.2). The analysis included 22 178 matched controls. Compared with lower potency statins, higher potency statins were associated with an increased rate of HCAP (HR: 1.14, 95% CI: 1.03-1.27). Higher potency statins were also associated with an increased rate of fatal HCAP (HR: 1.29, 95% CI: 1.04-1.59). CONCLUSIONS: Higher potency statins were not associated with a decreased risk of HCAP compared with lower potency statins.
AIM: Previous studies suggest that statins may have beneficial respiratory effects. However, it is unclear if these purported benefits vary with statin potency. Our objective was to determine if higher potency statins, compared with lower potency statins, were associated with a reduced risk of hospitalization for community-acquired pneumonia (HCAP). METHODS: We conducted a nested case-control analysis of a retrospective, population-based cohort of new users of statins using data extracted from the UK's Clinical Practice Research Datalink and Hospital Episode Statistics. For each HCAP case, we used risk set sampling to randomly select up to 10 controls, matched on sex, age, cohort entry date and follow-up duration. We used conditional logistic regression with high-dimensional propensity scores to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for HCAP with current use of higher potency statin vs. lower potency statins. RESULTS: A total of 217 721 patients entered the cohort on a lower potency statin and 130 707 entered on a higher potency statin; these patients resulted in 2251 cases of HCAP during 561 886 person-years of observation (rate: 4.0 HCAP per 1000 persons per year, 95% CI: 3.8-4.2). The analysis included 22 178 matched controls. Compared with lower potency statins, higher potency statins were associated with an increased rate of HCAP (HR: 1.14, 95% CI: 1.03-1.27). Higher potency statins were also associated with an increased rate of fatal HCAP (HR: 1.29, 95% CI: 1.04-1.59). CONCLUSIONS: Higher potency statins were not associated with a decreased risk of HCAP compared with lower potency statins.
Authors: Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood Journal: Eur Heart J Date: 2011-06-28 Impact factor: 29.983
Authors: Colin R Dormuth; Amanda R Patrick; William H Shrank; James M Wright; Robert J Glynn; Jenny Sutherland; M Alan Brookhart Journal: Circulation Date: 2009-04-06 Impact factor: 29.690
Authors: Sebastian Schneeweiss; Jeremy A Rassen; Robert J Glynn; Jerry Avorn; Helen Mogun; M Alan Brookhart Journal: Epidemiology Date: 2009-07 Impact factor: 4.822
Authors: Colin R Dormuth; Brenda R Hemmelgarn; J Michael Paterson; Matthew T James; Gary F Teare; Colette B Raymond; Jean-Philippe Lafrance; Adrian Levy; Amit X Garg; Pierre Ernst Journal: BMJ Date: 2013-03-18
Authors: Gerard J Criner; John E Connett; Shawn D Aaron; Richard K Albert; William C Bailey; Richard Casaburi; J Allen D Cooper; Jeffrey L Curtis; Mark T Dransfield; MeiLan K Han; Barry Make; Nathaniel Marchetti; Fernando J Martinez; Dennis E Niewoehner; Paul D Scanlon; Frank C Sciurba; Steven M Scharf; Don D Sin; Helen Voelker; George R Washko; Prescott G Woodruff; Stephen C Lazarus Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Colin R Dormuth; Kristian B Filion; J Michael Paterson; Matthew T James; Gary F Teare; Colette B Raymond; Elham Rahme; Hala Tamim; Lorraine Lipscombe Journal: BMJ Date: 2014-05-29
Authors: Sinéad M Langan; Sigrún A J Schmidt; Kevin Wing; Vera Ehrenstein; Stuart G Nicholls; Kristian B Filion; Olaf Klungel; Irene Petersen; Henrik T Sørensen; William G Dixon; Astrid Guttmann; Katie Harron; Lars G Hemkens; David Moher; Sebastian Schneeweiss; Liam Smeeth; Miriam Sturkenboom; Erik von Elm; Shirley V Wang; Eric I Benchimol Journal: CMAJ Date: 2019-06-24 Impact factor: 8.262
Authors: Sinéad M Langan; Sigrún Aj Schmidt; Kevin Wing; Vera Ehrenstein; Stuart G Nicholls; Kristian B Filion; Olaf Klungel; Irene Petersen; Henrik T Sorensen; William G Dixon; Astrid Guttmann; Katie Harron; Lars G Hemkens; David Moher; Sebastian Schneeweiss; Liam Smeeth; Miriam Sturkenboom; Erik von Elm; Shirley V Wang; Eric I Benchimol Journal: BMJ Date: 2018-11-14